Anti-TNFα recommended over no treatment for induction and maintenance of remission for adult outpatients
FRIDAY, June 4, 2021 (HealthDay News) — In clinical practice guidelines from the American Gastroenterological Association (AGA) published in the June 1 issue of Gastroenterology, recommendations are presented for the management of moderate-to-severe luminal and fistulizing Crohn disease (CD) in adult outpatients.
Joseph D. Feuerstein, M.D., from Beth Israel Deaconess Medical Center in Boston and colleagues presented recommendations from the AGA for the medical management of moderate-to-severe luminal and fistulizing CD in adult outpatients.
The authors recommend use of anti-tumor necrosis factor α (TNFα) over no treatment for induction and maintenance of remission in adult outpatients with moderate-to-severe CD. In addition, vedolizumab is suggested over no treatment and ustekinumab is recommended over no treatment. The AGA recommends against natalizumab over no treatment for induction and maintenance of remission. Infliximab, adalimumab, or ustekinumab are recommended over certolizumab pegol, and vedolizumab is suggested over certolizumab pegol for induction of remission in adult outpatients with moderate-to-severe CD who are naive to biologic drugs. Use of ustekinumab is recommended and vedolizumab is suggested over no treatment for remission induction in adult outpatients with moderate-to-severe CD who never responded to anti-TNFα.
“With many new drugs entering the market, clinician’s ability to treat patients with Crohn’s disease has improved greatly over the last 20 years,” Feuerstein said in a statement. “We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery.”
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
CDC: 1 in 10 U.S. Adults Reported GLP-1 Medication Use July to August 2025
β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Characteristics of Individuals Diagnosed With Autism Have Changed Since 2010
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions